Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
FDMT

FDMT - 4D Molecular Therapeutics, Inc. Stock Price, Fair Value and News

$8.60+0.11 (+1.30%)
Market Closed

35/100

FDMT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

35/100

FDMT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$6.92

Target 3M

$7.69

Target 6M

$7.42

FDMT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FDMT Price Action

Last 7 days

11.8%

Last 30 days

12.0%

Last 90 days

-24.0%

Trailing 12 Months

85.0%

FDMT RSI Chart

FDMT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FDMT Valuation

Market Cap

402.2M

Price/Earnings (Trailing)

-1.92

Price/Sales (Trailing)

3.4K

Price/Free Cashflow

-2.17

FDMT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$6.92

Target 3M

$7.69

Target 6M

$7.42

FDMT Fundamentals

FDMT Revenue

Revenue (TTM)

120.0K

Rev. Growth (Yr)

2.9K%

Rev. Growth (Qtr)

500%

FDMT Earnings

Earnings (TTM)

-209.2M

Earnings Growth (Yr)

-29.73%

Earnings Growth (Qtr)

-4.06%

FDMT Profitability

Return on Equity

-56.69%

Return on Assets

-49.34%

Free Cashflow Yield

-46.01%

FDMT Investor Care

Buy Backs (1Y)

15.81%

Diluted EPS (TTM)

-3.75

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202523.0K33.0K120.0K0
202415.6M10.4M5.2M37.0K
20232.2M2.3M22.0M20.7M
202217.3M2.8M2.0M3.1M
202114.7M15.8M16.9M18.0M
20208.6M10.3M12.0M13.6M
20190007.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About 4D Molecular Therapeutics, Inc.

FDMT
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
 CEO
 WEBSITE4dmoleculartherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES137

4D Molecular Therapeutics, Inc. Frequently Asked Questions

FDMT is the stock ticker symbol of 4D Molecular Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of 4D Molecular Therapeutics, Inc. is 402.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check FDMT's fair value in chart for subscribers.

The fair value guage provides a quick view whether FDMT is over valued or under valued. Whether 4D Molecular Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact 4D Molecular Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FDMT.

As of Wed Jan 28 2026, FDMT's PE ratio (Price to Earnings) is -1.92 and Price to Sales (PS) ratio is 3.35 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FDMT PE ratio will change depending on the future growth rate expectations of investors.